NKE
NIKE, Inc.
NKE offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
SGHC
Super Group (SGHC) Limited
SGHC has the edge over NKE overall, supported by stronger modeled upside and stronger fundamentals.
NKE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Strong |
NKE's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
SGHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Strong |
SGHC's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
NKE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $37.76 | — |
| Cheap | 23x | $47.70 | +26% |
| Forward | 30x | $37.76 | — |
| Fair | 33x | $68.16 | +80% |
| Expensive | 47x | $97.86 | +159% |
Historical ranges are pointers, not guarantees.
NKE has the edge over SGHC in the historical PE scenario, which offers more potential upside but is not a forecast.
SGHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.6x | $4.10 | -64% |
| Forward | 13x | $11.42 | — |
| Current | 16x | $11.42 | — |
| Fair | 23x | $16.77 | +47% |
| Expensive | 52x | $37.98 | +233% |
Historical ranges are pointers, not guarantees.
SGHC's PE is in its fair range at 16x. If earnings grow as analysts expect, today's price would be 13x next year's earnings, in its cheap range.
NKE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Stable | |
| Decline | |
| Improving | |
| Moderate | |
| Low |
Analysts expect NKE's profitability to improve, but its revenue to decline. However, they disagree widely on these estimates.
SGHC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
SGHC has the edge over NKE on the outlook, with more favorable valuation and earnings expectations.
NKE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.27 | -39% |
| Q3 2026 | $2.09 | +7.2% |
| Q2 2026 | $2.10 | -2.8% |
| Q1 2026 | $1.51 | -50% |
| Q4 2025 | $1.70 | -48% |
| Q3 2025 | $1.95 | -44% |
| Q2 2025 | $2.16 | -42% |
| Q1 2025 | $3.01 | -11% |
| Q4 2024 | $3.24 | -5.3% |
NKE's earnings per share have fallen from their peak: $2.09 over the past year, against $3.82 in late 2021.
SGHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.87 | +19% |
| Q2 2026 | $0.73 | +161% |
| Q1 2026 | $0.48 | +66% |
| Q4 2025 | $0.44 | +69% |
| Q3 2025 | $0.46 | +2200% |
| Q2 2025 | $0.28 | +1300% |
| Q1 2025 | $0.29 | +262% |
| Q4 2024 | $0.26 | +$0.28 |
| Q3 2024 | $0.02 | -80% |
SGHC has the edge over NKE on earnings, with more consistent year-over-year improvement.
NKE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.2B | -4.3% |
| Q2 2026 | $11B | -1.1% |
| Q1 2026 | $11.3B | +0.1% |
| Q4 2025 | $12.4B | +0.6% |
| Q3 2025 | $11.7B | +1.1% |
| Q2 2025 | $11.1B | -12% |
| Q1 2025 | $11.3B | -9.3% |
| Q4 2024 | $12.4B | -7.7% |
NKE's revenue fell from its 2023 peak and has held roughly level since: $11.2B last quarter, down 4.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.2% | +0.3 points |
| Q2 2026 | 12% | +9.2 points |
| Q1 2026 | 5.8% | -1.7 points |
| Q4 2025 | 8% | -3.4 points |
| Q3 2025 | 7.9% | -3.4 points |
| Q2 2025 | 2.9% | -11 points |
| Q1 2025 | 7.5% | -3.8 points |
| Q4 2024 | 11% | -2.9 points |
NKE's operating margin was 8.2% last quarter, about level with the same quarter a year ago.
SGHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $684M | +0.3% |
| Q1 2026 | $612M | +8% |
| Q4 2025 | $578M | +21% |
| Q3 2025 | $555.7M | +11% |
| Q2 2025 | $681.7M | +48% |
| Q1 2025 | $566.8M | +24% |
| Q4 2024 | $476.5M | +19% |
| Q3 2024 | $499.8M | +26% |
SGHC has the edge over NKE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 25% | +7 points |
| Q1 2026 | 20% | +2.7 points |
| Q4 2025 | 17% | -4.2 points |
| Q3 2025 | 25% | +20 points |
| Q2 2025 | 18% | +4.5 points |
| Q1 2025 | 17% | +12 points |
| Q4 2024 | 22% | +23 points |
| Q3 2024 | 5.5% | -2.3 points |
SGHC has the edge over NKE on profitability, with a higher operating margin.
NKE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$64M | -527% |
| Q2 2026 | $1.5B | +313% |
| Q1 2026 | $284M | -83% |
| Q4 2025 | $386M | -58% |
| Q3 2025 | $15M | -95% |
| Q2 2025 | $363M | -85% |
| Q1 2025 | $1.7B | -11% |
| Q4 2024 | $920M | -65% |
NKE usually generates cash, though not every quarter: the latest was −$64M, but it generated $2.1B over the past year.
SGHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $164M | +$286.3M |
| Q1 2026 | $89M | -63% |
| Q4 2025 | $0 | $0 |
| Q3 2025 | $0 | $0 |
| Q2 2025 | -$122.3M | -$122.3M |
| Q1 2025 | $241M | +$241M |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
SGHC has the edge over NKE on cash flow, with more consistent year-over-year improvement.
NKE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +3.2M shares |
| 1 year | +0.4% | +5.2M shares |
| 3 years | -3.8% | -59.1M shares |
| 5 years | -8.4% | -135M shares |
| Available history | -6.9% | -110M shares |
NKE has the edge over SGHC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $20M |
| Q3 2025 | $126M |
| Q2 2025 | $199M |
| Q1 2025 | $506M |
| Q4 2024 | $1.1B |
NKE has spent almost nothing on buybacks in the past year.
SGHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +2.8M shares |
| 1 year | +1.9% | +9.3M shares |
| 3 years | +2.2% | +11.2M shares |
| 5 years | +4.6% | +22.4M shares |
SGHC has 511M diluted shares, up 1.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
SGHC hasn't bought back shares in the past year.
NKE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.2x | Very low |
| Q2 2026 | 0.1x | Very low |
| Q1 2025 | 0.1x | Very low |
| Q4 2024 | 0.2x | Very low |
| Q3 2024 | 0.1x | Very low |
| Q2 2024 | -0.1x | Net Cash |
| Q1 2024 | -0.0x | Very low |
| Q4 2023 | 0.1x | Very low |
NKE's net debt is less than a year of its operating earnings (EBITDA).
SGHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.7x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
| Q4 2025 | -0.8x | Net Cash |
| Q3 2025 | -1.0x | Net Cash |
| Q2 2025 | -0.9x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -1.1x | Net Cash |
| Q3 2024 | -1.8x | Net Cash |
SGHC has the edge over NKE on leverage, with a lower net debt burden relative to earnings.
NKE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.0 | Neutral |
| Stochastic | 57.5 | Neutral |
NKE's weekly RSI is 40 (neutral) and its Stochastic is 58 (neutral).
SGHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.4 | Neutral |
| Stochastic | 19.2 | Oversold |
SGHC's weekly RSI is 42 (neutral) and its Stochastic is 19 (oversold).
NKE PE vs Consumer Cyclical Sector
| Metric | NKE | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 18x | 0.3% above |
| PE % | 2 | 47 | 45 pts below |
NKE is trading at 18x earnings, in line with the Consumer Cyclical sector's median of 18x.
SGHC PE vs Consumer Cyclical Sector
| Metric | SGHC | Sector median | Relative |
|---|---|---|---|
| PE | 16x | 18x | 13% below |
| PE % | 34 | 49 | 15 pts below |
SGHC has the edge over NKE on valuation relative to its sector.
NKE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.7 | 2.8% above |
| 20 week MA | $39.2 | 3.6% below |
| 50 week MA | $48.0 | 21% below |
| 100 week MA | $58.4 | 35% below |
| 200 week MA | $79.2 | 52% below |
NKE has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 52% below its 200-week average.
SGHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.2 | 1.6% above |
| 20 week MA | $12.8 | 11% below |
| 50 week MA | $12.0 | 4.6% below |
| 100 week MA | $10.8 | 6.1% above |
| 200 week MA | $7.19 | 59% above |
SGHC has the edge over NKE on trend strength, trading above more of its moving averages.
NKE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $101.6 | $141.6 | +39% |
| 2021 | $141.6 | $165.7 | +17% |
| 2022 | $165.7 | $116.3 | -30% |
| 2023 | $116.3 | $108.6 | -6.6% |
| 2024 | $108.6 | $76.4 | -30% |
| 2025 | $76.4 | $60.9 | -20% |
| 2026 YTD | $60.9 | $37.8 | -38% |
NKE has finished four years in a row lower, and it's down 38% so far in 2026.
SGHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.73 | $10.2 | +4.6% |
| 2021 | $10.2 | $9.96 | -2.2% |
| 2022 | $9.96 | $2.96 | -70% |
| 2023 | $2.96 | $3.17 | +7.1% |
| 2024 | $3.17 | $6.10 | +92% |
| 2025 | $6.10 | $11.9 | +95% |
| 2026 YTD | $11.9 | $11.4 | -4.2% |
SGHC has the edge over NKE on returns for 2026, with the stronger performance.